CBD Science Group PLC CEO Dr Michael Raymont joined Proactive New York to discuss the London, England-based group's Series A funding round, on the Crowd for Angels platform.
Raymont says the privately-held company, which is developing plant-based cannabinoid pharmaceutical therapeutics to treat cancer related pain will look to raise £2 million at £0.50 per share, where it will use the funding to assess data from its upcoming clinical trials and to shore up its supply chain so it can continue to produce and supply its material.